Quantcast
Last updated on April 24, 2014 at 11:28 EDT

Latest Neurocrine Biosciences Inc. Stories

2014-03-04 16:25:14

Live Audio Webcast will be on March 11, 2014 SAN DIEGO, March 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26(th) Annual Roth Conference in Laguna. The live presentation takes place on Tuesday, March 11 at 9:30am PT (12:30pm ET). The presentation will be webcast and may be accessed on the Company's website at...

2014-02-27 20:23:03

Live Audio Webcast will be on March 4, 2014 SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34(th) Annual Health Care Conference in Boston. The live presentation takes place on Tuesday, March 4 at 9:20am ET (6:20am PT). The presentation will be webcast and may be accessed on the Company's website at...

2014-02-26 20:22:32

SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or...

2014-02-25 16:29:29

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is...

2014-02-25 08:31:24

DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement...

2014-02-07 12:23:28

Live Audio Webcast will be on February 12, 2014 SAN DIEGO, Feb. 7, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Global Healthcare Conference in New York City. The live presentation takes place on Wednesday, February 12 at 10:15am ET (7:15am PT). The presentation will be webcast and may be accessed on the Company's website at...

2014-02-06 16:27:47

PROVIDES UPDATE ON RAPIDLY ADVANCING PIPELINE AND FINANCIAL GUIDANCE FOR 2014 SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2013. For the fourth quarter of 2013, the Company reported a net loss of $10.6 million, or $0.16 loss per share, compared to net income of $9.5 million, or income of $0.14 per fully diluted share, for the same period in 2012. For the year...

2014-02-04 08:36:46

Conference Call and Webcast Scheduled For Thursday, February 6, 2014 SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2013 financial results after the Nasdaq market closes on Thursday, February 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 6, 2014 at 5:00...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...

2014-01-09 08:27:59

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 9, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Fonar Corp. (NASDAQ: FONR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), and Neurocrine Biosciences Inc. (NASDAQ: NBIX). Today's readers may access these reports free of charge - including full price targets,...